Four products, two molecules, and a sharp difference between them. PT-141 exists as an approved medicine in the United States, under a narrow indication. Melanotan II exists nowhere as an approved medicine and carries warnings from three national regulators.
Both are sold here as research material. This page states the status of each plainly, because the gap between them is the single most useful thing to know before choosing.
PT-141 (Bremelanotide) 10 mg by Genheal
100,00 złAdd to cart3 in stock (can be backordered)
MT-2 (Melanotan II) 10 mg by Genheal
90,00 złAdd to cart4 in stock (can be backordered)
MT-2 (Melanotan II) 10 mg by Bio-Peptide
95,00 złAdd to cart6 in stock (can be backordered)
PT-141 (Bremelanotide) 10 mg by Bio-Peptide
105,00 złAdd to cartAvailable on backorder
What is in this category
| Product | Vial | Manufacturer |
|---|---|---|
| PT-141 (bremelanotide) | 10 mg | Bio-Peptide |
| PT-141 (bremelanotide) | 10 mg | Genheal |
| MT-2 (Melanotan II) | 10 mg | Bio-Peptide |
| MT-2 (Melanotan II) | 10 mg | Genheal |
Prices are on each product page, in Polish zloty. Shipping abroad and payment are described on the shipping and payments page.
PT-141: an approved medicine under another name
Bremelanotide is one of the few molecules in this shop with a drug approval behind it. The United States Food and Drug Administration approved it on 21 June 2019 under the trade name Vyleesi. The indication is narrow: premenopausal women with acquired, generalised hypoactive sexual desire disorder, where it causes marked distress or interpersonal difficulty and does not stem from another condition, medication or relationship problem.
It is a melanocortin receptor agonist. The product label states outright that the way the drug improves desire is not known. In the registration trials the effect was moderate: an increase of 1.2 points or more on the desire score was recorded in roughly 25 percent of treated participants, against roughly 17 percent on placebo.
The approved medicine is given as a subcutaneous injection in the abdomen or thigh, from a ready autoinjector, at least 45 minutes before planned sexual activity. It is used as needed, not daily.
One thing needs saying without hedging: the peptide sold as research material is not Vyleesi. The same molecule in a registered medicine comes with a known dose, pharmaceutical quality control and an autoinjector. Those three things are what you are not buying here.
Melanotan II: unlicensed, with regulator warnings
Melanotan II is a synthetic form of alpha-MSH, the melanocyte stimulating hormone, and it produces skin pigmentation. It is unlicensed and largely unstudied, with no approval for any medical use in any country.
It should not be confused with afamelanotide, sometimes called melanotan I, which is an approved medicine for erythropoietic protoporphyria, a rare blood disorder. Melanotan II is a different molecule with no registration.
Three regulators have acted on it. The British MHRA warned in November 2008 that the safety of these products is unknown and that advertising and selling them in the United Kingdom is illegal. The United States FDA issued a warning to the distributor Melanocorp Inc. on 7 February 2007 over unlawful sale and marketing. The Australian TGA published an alert after finding that tested Melanotan II products had inconsistent amounts of the substance.
Reported short-term effects include facial flushing, reduced appetite, nausea and vomiting, and in men spontaneous erections with yawning. Reported long-term effects include melanoma, darkening and appearance of new moles, nail discolouration, rhabdomyolysis, meaning muscle cell breakdown, and encephalopathy syndrome. Contamination from improper preparation is a separate risk.
The darkening of moles is not merely cosmetic. It makes melanoma harder to detect, which is the reason this paragraph sits here rather than in a footnote.
Practical notes
Both molecules arrive as lyophilised powder and are reconstituted the same way as any other peptide: bacteriostatic water added down the wall of the vial, no shaking, refrigerated afterwards. The procedure is in reconstituting a peptide, and the storage limits in storing peptides. Verification of the vial is described in how to spot a counterfeit peptide.
Frequently asked questions
Is PT-141 the same as Vyleesi?
It is the same molecule, but not the same product. Vyleesi is a registered medicine with a known dose, quality control and an autoinjector; research material has none of those.
How effective was bremelanotide in trials?
Moderately. An increase of 1.2 points or more on the desire score was seen in about 25 percent of treated participants, against about 17 percent on placebo.
Is Melanotan II approved anywhere?
No. It has no approval for any medical use in any country, and regulators in the United Kingdom, the United States and Australia have issued warnings about it.
Is Melanotan II the same as melanotan I?
No. Melanotan I, afamelanotide, is an approved medicine for a rare blood disorder. Melanotan II is a different, unregistered molecule.
What are the reported risks of Melanotan II?
Short term: flushing, reduced appetite, nausea and vomiting. Long term, reports include melanoma, darkening and new moles, nail discolouration, rhabdomyolysis and encephalopathy syndrome.